Indeed, the reversal of aberrant hypermethylation by inhibiting DNMT1 promoted anticancer activity, especially in hematologic malignancies [6]; this finding partially explains the relevance of DNMT1 as a therapeutic target. This evidence concerns the gene DNMT1 and hematologic disorder.